Publications by authors named "Russell Braeuer"

Article Synopsis
  • Idiopathic pulmonary fibrosis (IPF) is characterized by ongoing tissue damage and scarring in the lungs, driven by persistent activation of mesenchymal cells related to various signaling pathways.
  • The study focuses on the role of the transcription factor NFAT1, which controls a key profibrotic mediator (autotaxin) in lung mesenchymal cells, finding that mice lacking NFAT1 have improved survival and less lung fibrosis after injury.
  • The research indicates that NFAT1 activates profibrotic processes in IPF and suggests it could be a potential target for therapeutic intervention in treating the disease.
View Article and Find Full Text PDF

In this study, we demonstrate that forkhead box F1 (FOXF1), a mesenchymal transcriptional factor essential for lung development, was retained in a topographically distinct mesenchymal stromal cell population along the bronchovascular space in an adult lung and identify this distinct subset of collagen-expressing cells as key players in lung allograft remodeling and fibrosis. Using Foxf1-tdTomato BAC (Foxf1-tdTomato) and Foxf1-tdTomato Col1a1-GFP mice, we show that Lin-Foxf1+ cells encompassed the stem cell antigen 1+CD34+ (Sca1+CD34+) subset of collagen 1-expressing mesenchymal cells (MCs) with a capacity to generate CFU and lung epithelial organoids. Histologically, FOXF1-expressing MCs formed a 3D network along the conducting airways; FOXF1 was noted to be conspicuously absent in MCs in the alveolar compartment.

View Article and Find Full Text PDF
Article Synopsis
  • FOXF1 is a transcription factor that helps regulate lung mesenchymal stromal cells (LR-MSCs) and is found in lower levels in fibrotic cells compared to non-fibrotic ones.
  • Silencing FOXF1 increases the migratory ability of LR-MSCs by upregulating genes involved in proliferation and inflammation, as well as enhancing the activity of Autotaxin (ATX).
  • FOXF1 represses ATX through specific binding sites in its promoter, and the promotion of LR-MSC migration due to FOXF1 loss can be counteracted by inhibiting ATX and its receptor, LPA1.
View Article and Find Full Text PDF
Article Synopsis
  • Understanding the mechanisms behind allograft fibrosis and chronic graft failure is crucial for improving transplant outcomes, particularly in cases of restrictive allograft syndrome (RAS).
  • Researchers used a specific lung transplant model to show that humoral immune responses, especially involving B cells, play a significant role in developing RAS.
  • Findings indicated that blocking B cell activity reduced fibrosis in lung allografts, suggesting targeted therapies could improve management of different types of chronic lung allograft dysfunction.
View Article and Find Full Text PDF
Article Synopsis
  • Histopathologic studies indicate that chronic lung allograft dysfunction (CLAD) involves inflammation from mononuclear cells (MNC) and growth from mesenchymal cells (MC), with interleukin 6 (IL-6) playing a key role in their interaction.
  • Analysis of bronchoalveolar lavage fluid shows that IL-6 and its receptor levels are significantly higher in CLAD-affected lungs compared to before the onset of the disease.
  • Research suggests that MNCs increase IL-6 production when interacting with MCs, leading to enhanced MC activity and fibrosis, while experiments on mice demonstrate that blocking IL-6 can significantly reduce lung fibrosis.
View Article and Find Full Text PDF

Background: Chronic lung allograft dysfunction (CLAD), the primary cause of poor outcome after lung transplantation, arises from fibrotic remodeling of the allograft and presents as diverse clinical phenotypes with variable courses. Here, we investigate whether bronchoalveolar lavage (BAL) mesenchymal cell activity at CLAD onset can inform regarding disease phenotype, progression, and survival.

Methods: Mesenchymal cell colony-forming units (CFUs) were measured in BAL obtained at CLAD onset (n = 77) and CLAD-free time post-transplant matched controls (n = 77).

View Article and Find Full Text PDF

Nuclear factor of activated T cell (NFAT1, NFATC2) is a transcription factor that binds and positively regulates IL2 expression during T-cell activation. NFAT1 has important roles in both innate and adaptive immune responses, but its involvement in cancer is not completely understood. We previously demonstrated that NFAT1 contributes to melanoma growth and metastasis by regulating the autotaxin gene (Enpp2).

View Article and Find Full Text PDF
Article Synopsis
  • Recent studies reveal that A-to-I RNA editing in microRNAs impacts tumor growth and metastasis, but its effects in melanoma are unclear.
  • Evidence shows that low expression of ADAR1 in metastatic melanoma is linked to CREB, and re-introduction of ADAR1 suppresses tumor growth and metastasis.
  • The miRNA miR-455-5p, which has A-to-I editing sites, functions differently when edited; the unedited form promotes melanoma metastasis, while the edited version inhibits it, highlighting the role of RNA editing in cancer progression.
View Article and Find Full Text PDF

Malignant melanoma is one of the most aggressive cancers and can disseminate from a relatively small primary tumor and metastasize to multiple sites, including the lung, liver, brain, bone, and lymph nodes. Elucidating the molecular and genetic changes that take place during the metastatic process has led to a better understanding of why melanoma is so metastatic. Herein, we describe the unique features that distinguish melanoma from other solid tumors and contribute to the malignant phenotype of melanoma cells.

View Article and Find Full Text PDF

Background: The pharmaceutical and biotechnology industries depend on findings from academic investigators prior to initiating programs to develop new diagnostic and therapeutic agents to benefit cancer patients. The success of these programs depends on the validity of published findings. This validity, represented by the reproducibility of published findings, has come into question recently as investigators from companies have raised the issue of poor reproducibility of published results from academic laboratories.

View Article and Find Full Text PDF

Melanoma is the deadliest form of skin cancer in which patients with metastatic disease have a 5-year survival rate of less than 10%. Recently, the overexpression of a β-galactoside binding protein, galectin-3 (LGALS3), has been correlated with metastatic melanoma in patients. We have previously shown that silencing galectin-3 in metastatic melanoma cells reduces tumor growth and metastasis.

View Article and Find Full Text PDF

The progression of melanoma toward the metastatic phenotype occurs in a defined stepwise manner. While many molecular changes take place early in melanoma development, progression toward the malignant phenotype, most notably during the transition from the radial growth phase (RGP) to the vertical growth phase (VGP) involves deregulated expression of several transcription factors. For example, the switch from RGP to VGP is associated with the loss of the transcription factor AP2α and gain of transcriptional activity of cAMP-responsive element binding protein.

View Article and Find Full Text PDF

Melanoma is the leading cause of skin cancer-related deaths, which is due in large part to its aggressive behavior, resistance to therapy, and ability to metastasize to multiple organs such as the lymph nodes, lung, and brain. Melanoma progresses in a stepwise manner from the benign nevus, to radial spreading through the dermis, to a vertical invasive phase, and finally to metastasis. The carbohydrate-binding family of galectins has a strong influence on each phase of melanoma progression through their effects on immune surveillance, angiogenesis, cell migration, tumor cell adhesion, and the cellular response to chemotherapy.

View Article and Find Full Text PDF

The acquisition of the metastatic melanoma phenotype is associated with increased expression of the melanoma cell adhesion molecule MCAM/MUC18 (CD146). However, the mechanism by which MUC18 contributes to melanoma metastasis remains unclear. Herein, we stably silenced MUC18 expression in two metastatic melanoma cell lines, A375SM and C8161, and conducted cDNA microarray analysis.

View Article and Find Full Text PDF

The thrombin receptor protease activated receptor-1 (PAR-1) is overexpressed in metastatic melanoma cell lines and tumor specimens. Previously, we demonstrated a significant reduction in tumor growth and experimental lung metastasis after PAR-1 silencing via systemic delivery of siRNA encapsulated into nanoliposomes. Gene expression profiling identified a 40-fold increase in expression of Maspin in PAR-1-silenced metastatic melanoma cell lines.

View Article and Find Full Text PDF

The molecular changes associated with the transition of melanoma cells from radial growth phase (RGP) to vertical growth phase (VGP) and the metastatic phenotype are not very well defined. However, some of the genes involved in this process and their transcriptional regulation are beginning to be elucidated. For example, the switch from RGP to VGP and the metastatic phenotype is associated with loss of the AP-2α transcription factor.

View Article and Find Full Text PDF

Background: The loss of AP-2alpha and increased activity of cAMP-responsive element binding (CREB) protein are two hallmarks of malignant progression of cutaneous melanoma. However, the molecular mechanism responsible for the loss of AP-2alpha during melanoma progression remains unknown.

Methodology/principal Findings: Herein, we demonstrate that both inhibition of PKA-dependent CREB phosphorylation, as well as silencing of CREB expression by shRNA, restored AP-2alpha protein expression in two metastatic melanoma cell lines.

View Article and Find Full Text PDF